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Background: Genetics play a signiﬁcant role in the etiology of late-life neurodegenerative
diseases like Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia.
Part of the individual differences in risk for these diseases can be traced back decades
before the onset of disease symptoms. Previous studies have shown evidence for
plausible links of apolipoprotein E (APOE), the most important genetic marker for
Alzheimer’s disease, with early-life cognition and neuroimaging markers. We aimed to
assess whether genome-wide genetic burden for the aforementioned neurodegenerative
diseases plays a role in early-life processes.
Methods: We studied children from the Generation R Study, a prospective birth cohort.
APOE genotypes and polygenic genetic burdens for Alzheimer’s disease, Parkinson’s
disease, and frontotemporal dementia were obtained through genome-wide genotyping.
Non-verbal intelligence was assessed through cognitive tests at the research center
around the age of 6 years, and educational attainment through a national school
performance test around the age of 11 years. The Child Behavior Checklist was
administered around the age of 10 years, and data from the anxious/depressed,
withdrawn/depressed, and the internalizing behavior problems scales were used.
Children participated in a neuroimaging study when they were 10 years old, in which
structural brain metrics were obtained. Lipid serum proﬁles, which may be inﬂuenced by
APOE genotype, were assessed from venal blood obtained around the age of 6 years. The
sample size per analysis varied between 1,641 and 3,650 children due to completeness
of data.
Results:We did not ﬁnd evidence that APOE genotype or the polygenic scores impact on
childhood nonverbal intelligence, educational attainment, internalizing behavior, and
global brain structural measures including total brain volume and whole brain fractional
anisotropy (all p > 0.05). Carriership of the APOE e2 allele was associated with lower andg February 2020 | Volume 11 | Article 331
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Frontiers in Psychiatry | www.frontiersin.orAPOE e4 with higher low-density lipoprotein cholesterol concentrations when compared
to APOE e3/e3 carriers.
Conclusion: We found no evidence that genetic burden for late-life neurodegenerative
diseases associates with early-life cognition, internalizing behavior, or global
brain structure.Keywords: polygenic risk scores, Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, cognition,
neuroimaging, lipid proﬁles, internalizing behaviorINTRODUCTION
Genetic factors play a signiﬁcant role in the etiology of late-life
neurodegenerative diseases like Alzheimer’s disease (AD) (1, 2),
Parkinson’s disease (PD) (3), and frontotemporal dementia
(FTD) (4). With the exception of rare Mendelian forms of
diseases, cases arise due to multifactorial processes where many
genetic variants confer risk of neurodegeneration, in
combination with non-genetic factors. The clinical onset of the
aforementioned diseases tends to be preceded by years of
deterioration of cognition and brain structure (5–7) as well as
an increased incidence of depressive and psychiatric symptoms
(8–10). For AD, these differences may even extend decades
before the onset of disease (11–13), which could partly be
explained by individual differences in the genetic burden for
AD. As the genome is stable throughout life, the genes implicated
in late-life neurodegenerative disease may already lead to subtle
differences during childhood.
The apolipoprotein E epsilon 4 allele (APOE e4) is the
strongest common genetic variant for AD (14–16). The APOE
gene plays a role in lipoprotein metabolism, and has been shown
to affect lipid serum proﬁles during adulthood (17–21), and
potentially during childhood (22, 23). As APOE also increases
the risk for AD, its role in early-life cognition and brain markers
has also been studied. The studies on APOE e4 and cognition
during adolescence and early adulthood have reported mixed
results, with some reporting lower cognitive function, some
higher, and most reporting no difference (24). Additionally, a
number of studies showed that APOE e4 may relate to lower
brain volumes during infancy and childhood, particularly in
regions affected in AD such as the hippocampus (25–30).
Overall, APOE e4 may associate with early-life processes, but
this needs to be elucidated further.
With the advent of genome-wide association studies (GWAS)
there has been an increase in the number of genes identiﬁed for
neurodegenerative disease. GWAS has led to the discovery of at
least 30 new genetic loci for AD (1, 2), at least genetic 24 loci for
PD (3), and at least 3 loci for FTD (4). The disease burden per
locus can be combined into a single score, known as polygenic
risk scores (PGRS), to assess the genetic burden a person has for
that disease (31). The genetic burden for AD, PD, and FTD may
relate to early-life processes, which can be studied using PGRS.
However, few studies exist that assesses the effect of such PGRS
on early-life markers.
To obtain a more comprehensive overview of the relevance in
early-life of genes related to late-life neurodegenerative diseaseg 2we performed a comprehensive study within the Generation R
birth cohort. We assessed the APOE genotype and created PGRS
for AD, PD, and FTD. Given the existing literature we
hypothesized that these genetic predispositions to late-life
neurodegenerative disorders associate with early-life non-
verbal intelligence quotient (IQ), educational attainment,
internalizing behavior, and neuroimaging markers, and that
APOE and the AD PGRS associate with lipid proﬁles.METHODS
Participants
The data was obtained from the Generation R cohort, a
prospective birth cohort based in Rotterdam, the Netherlands
(32). Pregnant women in Rotterdam were at their ﬁrst prenatal
visit approached to participate. A total of 9,901 children were
born as part of the Generation R cohort and were invited to
participate in questionnaires and research center visits beginning
in 2002 to the present day.
DNA was sequenced from blood obtained from the umbilical
cord or with blood samples collected around 6 years of age, and
genetic data was available for 5,725 children. In the case of sibling
pairs (n = 235 pairs) we included the oldest sibling. This led to a
sample of 5,490 children. The focus of the current study was on
cognitive function, brain structure, and blood lipid proﬁles. Non-
verbal IQ was measured at approximately 6 years (n = 3,650) and
educational attainment at 11 years of age (n = 1,641). The
Childhood Behavior Checklist (CBCL) was administered
around the age of 10 years with data for the anxious/depressed
scale (n = 1,867), the withdrawn/depressed scale (n = 1,862), and
the internalizing problems scale (n = 1,859) used for this study.
Magnetic resonance imaging (MRI) of the brain was done when
the children were approximately 10 years of age, collecting both
T1-weighted (n = 1,962) and diffusion-weighted images (n =
1,832). Blood lipid proﬁles were determined with blood samples
obtained around the age of 6 years (n = 2,749). A ﬂow chart of
the study population is shown in Supplementary Figure 1.Ethics Statement
The study was conducted in accordance with the guidelines as
proposed in the World Medical Association Declaration of
Helsinki and was approved by the Medical Ethics Committee
of the Erasmus MC. Written informed consent was obtained
from primary caregivers on behalf of the child.February 2020 | Volume 11 | Article 33
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Polygenic Risk Scores
DNA sample collection, genotype calling procedures, and
subsequent quality control have been described elsewhere (33,
34). In brief, samples were either collected from cord blood at
birth (Illumina 610K Quad Chip) or from venipuncture at a visit
to the research center when children were between the age of 5
and 8 years (Illumina 660K Quad Chip). Single nucleotide
polymorphisms were ﬁltered for minor allele frequency < 0.01,
Hardy-Weinberg disequilibrium p < .00001, and missing rate >
0.05. To be able to account for population stratiﬁcation, we
calculated the ﬁrst 10 genomic components using the multi-
dimensional scaling function of PLINK (34, 35).
APOE carriership status was assessed from the genotyped
data and based on the nucleotide combinations of two single
nucleotide polymorphisms: rs429348 and rs7412. A thymine at
both locations is classiﬁed as APOE e2, one thymine and one
cytosine as APOE e1 or APOE e3, and both cytosines as APOE
e4. As APOE e1 and APOE e3 cannot be distinguished we
classiﬁed both as APOE e3. We considered APOE e3/e3 to be the
reference category as this is the most prevalent genotype.
PGRS for AD, PD, and FTD were calculated using PRSice-2
(36). The scores were based on summary statistics from the
largest GWAS for each respective neurodegenerative disease (3,
4, 37). PGRS are generally calculated for different thresholds of
statistical signiﬁcance in the summary statistics. As we did not
have an a priori hypothesis on the optimal threshold, we
calculated PGRS based on single nucleotide polymorphisms
below the following p-value thresholds: 0.000001, 0.000005,
0.00001, 0.000005, 0.00001, 0.00005, 0.0001, 0.0005, 0.01, 0.05,
0.1, 0.5, and 1.0. Strand ﬂips were corrected and we used
clumping to build the score using independent loci.Non-Verbal Intelligence Quotient
and Educational Attainment
Two measures for cognitive function were available. The ﬁrst was
an assessment of non-verbal IQ at the research visit around the
age of 6 years. Participants completed two subtests of the
Snijders-Oomen Non-Verbal Intelligence Test-Revised (SON-R
2½-7) (38): “Mosaics,” a spatial visualization task, and
“Categories,” an abstract reasoning task. The raw scores were
converted to IQ scores using age and sex-speciﬁc norms. As both
tasks speciﬁcally assess non-verbal cognition, we considered
these scores as non-verbal IQ scores. The correlation between
IQ derived from the whole test battery and IQ derived from just
the “Mosaics” and “Categories” tests has been shown to be high
(r = 0.86) (39).
The measure of cognitive function was the educational
attainment score obtained at the age of 11 years. The “Centraal
Instituut voor Toetsontwikkeling” (CITO) test is administered in
the majority primary schools in the Netherlands and is
completed during the ﬁnal year of primary school. The CITO
test generally consists of two main skill domains: language and
mathematics. The raw test scores for both domains were
obtained for most Generation R children that took the CITO
test during the years 2014 to 2017 and that were still part ofFrontiers in Psychiatry | www.frontiersin.org 3Generation R at the time. As the test difﬁculty tends to vary
slightly each year we summed the raw domain scores to a total
score for each child, standardized the scores for all children
within a given year, and ﬁnally combined the stratiﬁed
distributions into one distribution. This method yielded
standardized scores that were comparable across testing years.
Child Behavior Checklist
Behavioral problems were assessed using the CBCL for ages 6 to
18 (40). The CBCL is a validated and reliable 113-item inventory
that uses caregiver-reported information to assess behavioral
problems in children. The procedure and speciﬁc characteristics
for Generation R have been described elsewhere (41). For this
study we considered mother-reported data on the anxious/
depressed, the withdrawn/depressed, and the internalizing
problems scales.
Image Acquisition and Processing
Image acquisition has been described elsewhere (41). In brief,
structural brain MR images were obtained on a single 3T GE
Discovery MR750w MRI system (General Electric, Milwaukee,
WI, USA) utilizing an eight-channel receive-only head coil. T1-
weighted images were collected using a three-dimensional (3D)
inversion recovery-prepared fast spoiled gradient recalled
sequence (TR = 8.77 ms, TE = 3.4 ms, TI = 600 ms, ﬂip angle =
10°, ﬁeld of view = 220 x 220 mm, acquisition matrix = 220 x 220,
slice thickness = 1 mm, number of slices = 230, bandwidth = 25
kHz). Diffusion-weighted images consisted of three b0 volumes
and 35 diffusion directions using an echo planar imaging
sequence (TR = 12,500 ms, TE = 72 ms, ﬁeld of view = 240 x
240 mm, acquisition matrix = 120 x 120, slice thickness = 2 mm,
number of slices = 65, b = 900 s/mm2).
T1-weighted images were processed through the FreeSurfer
analysis suite, version 6.0.0 (42). The procedure has been
described elsewhere (43). Brieﬂy, non-brain tissue was
removed, voxel intensit ies were normalized for B1
inhomogeneity, whole-brain tissue segmentation was
performed, and a surface-based model of the cortex was
reconstructed. For each participant we obtained metrics for
total brain volume, cortical gray matter volume, cerebrospinal
ﬂuid volume, and mean cortical thickness. For analyses of APOE
status and the AD PGRS we additionally focused on volumes of
the hippocampus, the entorhinal cortex, the middle temporal
gyrus, and the parahippocampal gyrus. For the PD PGRS we also
considered volumes of the nucleus accumbens, the caudate
nucleus, the globus pallidi, and the putamen. Finally, for the
FTD PGRS we also looked at the frontal and the temporal lobes,
and in particular the volume, the mean thickness, and the surface
area. For all lateralized structures we took the mean of both sides.
Diffusion tensor imaging (DTI) images were processed
through the FMRIB Software Library (FSL), version 5.0.9 (44).
The full procedure is described elsewhere (43). Brieﬂy, non-brain
tissue was removed and images were corrected for eddy-current
artifacts and translations/rotations resulting from head motion.
Diffusion tensors were ﬁtted at each voxel using the RESTORE
method from the Camino diffusion MRI toolkit (45). We further
performed probabilistic white matter ﬁber tractography in nativeFebruary 2020 | Volume 11 | Article 33
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identify connectivity distributions of a number of well-known
ﬁber bundles (46). Average fractional anisotropy and mean
diffusivity values were then computed for each white matter
tract. Global measures for fractional anisotropy and mean
diffusivity were obtained by performing factor analyses on the
tract-speciﬁc values (47).
Lipid Proﬁles
Lipid proﬁles of the children were assessed from venous blood
acquired during the research visits around the age of 6 years after
a 30 min fast. Serum total cholesterol, high-density lipoprotein
cholesterol (HDL-c), and triglyceride concentrations were
derived with the Roche cobas 8000 analyzer (Roche
Diagnostics GmbH, Penzberg, Germany), and low-density
lipoprotein cholesterol (LDL-c) was estimated using the
Friedewald equation (48). We considered these lipids in
relation to APOE status and the AD PGRS as the APOE gene
plays a signiﬁcant role in lipid metabolism (49), whereas we did
not have such a prior expectation for PD and FTD.
Statistical Analysis
Statistical analyses were performed with the R statistical package,
version 3.5.2 (R 50). We used multiple linear regression for all
outcomes, correcting for age at outcome measurement, sex of the
child, maternal education (low, intermediate, or high), and the
ﬁrst 10 genomic components. The latter was done to take into
account the underlying genetic structure of the population. The
serum lipid models were additionally adjusted for body mass
index (BMI) at the time of the venous puncture. The volumetric
neuroimaging models, i.e. cortical volume, cerebrospinal ﬂuid
(CSF) volume, and the disease-speciﬁc regional brain volumes,
were additionally adjusted for total brain volume. Furthermore,
we applied square-root transformations to the CBCL scales to
better satisfy the linearity assumption of linear regression.
Polygenic burden may only affect those whose burden is
above a certain threshold, thus leading to non-linearity of an
association. We assessed this through two approaches: 1)
dichotomization of the top PGRS decile versus the rest of the
population, 2) ﬁtting restrictive cubic splines on the PGRSs to
assess any non-linearity in the association.
Use of PGRS in the Generation R Study requires a critical
consideration of ethnicity. The GWAS from which we used the
summary statistics were based on populations of European
ancestry. Findings from GWAS and by extension PGRS are
speciﬁc to the ethnicity of the original study population. The
Generation R study is based in the city of Rotterdam, where
about half of all individuals are of non-European ancestry. We
focused our main ﬁndings on the complete population, but we
additionally stratiﬁed our analyses for European ancestry to
check for any effects related speciﬁcally to ethnicity. We
additionally performed sensitivity analyses where we did not
correct for the ﬁrst 10 genomic components, to see whether
improper correction for population stratiﬁcation is relevant for
studies on APOE and studies on AD, PD, and FTD PGRS (51).
Multiple testing correction was considered on three levels: 1)
the PGRS for AD, PD, or FTD, 2) the PGRS thresholds, and 3)Frontiers in Psychiatry | www.frontiersin.org 4the outcome measures. We did not expect dependence among
the PGRS of the neurodegenerative diseases. Therefore, we
applied a Bonferroni correction across AD, PD, and FTD. As
the PGRS thresholds were strongly intercorrelated as well as
some of the outcome measures, we applied a false discovery rate
(FDR) correction within a given disease. The p-values reported
below are those after the FDR correction.RESULTS
Population Characteristics
Table 1 shows the characteristics of the total study population
and stratiﬁed by European ancestry and non-European ancestry.
Overall, the most common APOE genotypes were e3/e3 (64.9%),
e2/e3 (11.5%), and e3/e4 (19.1%), whereas the other genotypes
were much less common, i.e. e2/e2 (0.5%), e2/e4 (2.3%), and e4/
e4 (1.6%). These numbers were similar for those with European
and non-European ancestry.Apolipoprotein E and Polygenic Risk
Scores for Alzheimer’s Disease
Figures 1 and 2 display the results of the associations of all relevant
outcomes with APOE genotype and AD PGRS, respectively.
Neither APOE genotype nor any AD PGRS associated with non-
verbal IQ during the 6-year visit or the CITO score at 11 years (all
pcorrected > 0.05). The APOE genotype and AD PGRS also did not
relate to global brain metrics such as total brain volume and CSF
volume, nor with the connectivity metrics global fractional
anisotropy and mean diffusivity (all pcorrected > 0.05). APOE
genotype and the AD PGRS also did not associate with region-
speciﬁc metrics for the hippocampus, the entorhinal cortex, the
medial temporal gyrus, and the parahippocampal region. Finally,
APOE genotype and AD PGRS did not show any statistically
signiﬁcant associations with the CBCL scales anxious/depressed
or withdrawn/depressed, nor with the internalizing problems scale
(all pcorrected > 0.05).
The APOE genotype associated with serum lipid proﬁles.
Compared to the APOE e3/e3 genotype, those with APOE e2/e3
had lower total cholesterol concentrations (b = −0.32, SE = 0.06,
pcorrected < 0.001), lower LDL-c concentrations (b = −0.57, SE =
0.06, pcorrected < 0.001), and higher HDL-c concentrations (b =
0.22, SE = 0.06, pcorrected = 0.01). The APOE e2/e2 followed the
exact same pattern but with even larger differences.
Compared to the APOE e3/e3 genotype those with e3/e4 had
higher total cholesterol concentrations (b = 0.19, SE = 0.05,
pcorrected = 0.003), higher LDL-c concentrations (b= 0.16, SE= 0.05,
pcorrected < 0.001), and lower HDL-c concentrations (b = 0.26, SE =
0.05, pcorrected = 0.02). These differences were similar and larger
when comparing the APOE e3/e3 genotype with the APOE e4/
e4 genotype.
Triglycerides were higher in all genotypes compared to APOE
e3/e3, although none of these were statistically signiﬁcance (all
pcorrected > 0.05).
TheADPGRS also associatedwith serum lipid proﬁles, but only
at stricter PGRS thresholds, i.e. PGRS thresholds below 0.001.February 2020 | Volume 11 | Article 33
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genotype as a covariate (all pcorrected > 0.05). Furthermore, the
results did not differ when using the top-decile PGRS
dichotomization rather than the continuous PGRS, or when
modeling cubic splines.
Polygenic Risk Scores for Parkinson’s
Disease and Frontotemporal Dementia
The results for the PD and FTD PGRS are shown in Figures 3
and 4, respectively. We found no support for associations of
scores at any threshold with non-verbal IQ, educational
attainment, internalizing behavior scales, or neuroimaging
markers. Furthermore, we did not ﬁnd evidence for
associations of the PD scores with the volumes of the nucleusFrontiers in Psychiatry | www.frontiersin.org 5accumbens (ß for PGRS at 0.05 threshold = −0.08, SE0.05 = 0.12,
pcorrected = 1.00), the caudate nucleus (ß0.05 = 0.03, SE0.05 = 0.12,
pcorrected = 1.00), the globus pallidus (ß0.05 = −0.07, SE0.05 =
0.13, pcorrected = 1.00), or the putamen (ß0.05 = −0.13, SE0.05 =
0.12, pcorrected = 1.00). Similarly, we did not observe any
associations of the FTD scores with the volumes of the frontal
(ß0.05 = −0.00, SE0.05 = 0.03, pcorrected = 1.00) or temporal lobes
(ß0.05 = 0.01, SE0.05 = 0.03, pcorrected = 1.00).
Population Structure
All analyses were performed in all available participants, and
were controlled for the ﬁrst 10 genomic components. We further
stratiﬁed the analyses for European versus non-European
ancestry (Figures 5A, D, Supplementary Figure 2), and the
effect estimates were generally similar. We additionally reran the
analyses without correcting for the genomic components, and
this led to stark changes in the results (Figures 5B, E,
Supplementary Figure 3). The higher the PGRS threshold, the
more statistically signiﬁcant ﬁndings were present in the analyses
not corrected for genomic components compared to when we
did correct for genomic components. We further split the
uncorrected analyses for European versus non-European
ancestry, to see whether one of these groups was driving the
sudden change in ﬁndings (Figures 5C, F, Supplementary
Figure 4). Within the uncorrected analyses for individuals of
non-European ancestry we ﬁnd an inﬂation of the number of
statistically signiﬁcant ﬁndings, whereas this was not the case for
individuals of European ancestry.DISCUSSION
None of the measures for genetic burden for AD, PD, or FTD
were associated with childhood non-verbal IQ, educational
attainment, internalizing behavior, global brain structure, or
disease-speciﬁc regional brain structures. Although genetic
burden for late-life neurodegenerative disease has been linked
to brain structure and cognitive function during late-life, we ﬁnd
no evidence that these affect the same processes during early life.
Furthermore, we provided clear evidence that the APOE
genotype affects lipid proﬁles during childhood. Finally, we
showed that improper control of the ethnic structure of the
population through genomic components can lead to false
positive associations when considering PGRS for AD, PD,
and FTD.
We found no support for the link between AD genetic burden
and global, hippocampal. and temporal regions although
previous studies have provided evidence for such links during
infancy (28, 29), childhood (25, 30, 52, 53), and early adulthood
(27, 54–61). The support for such associations does seem
stronger in studies during early adulthood than during
childhood. This suggests that the genetic burden for AD
becomes more relevant with age, and that there are cumulative
processes at play which may only become apparent after early-
life. For example, the pathological burden in APOE e4 carriers
may be increased due to accumulation of lipoprotein (62, 63),TABLE 1 | Characteristics of the study population.
Characteristics All European
ancestry
Non-European
ancestry
(N = 5,490) (N = 2,651) (N = 2,839)
APOE genotype (%)
e2/e2 0.5 0.5 0.6
e2/e3 11.5 10.4 12.6
e2/e4 2.3 2.5 2.1
e3/e3 64.9 60.6 69.0
e3/e4 19.1 21.6 16.8
e4/e4 1.6 2.2 1.1
Visit around 6 years
Non-verbal IQ (mean, SD) 101 (15) 105 (14) 97 (15)
Total cholesterol (mean, SD)
(mmol/L)
4.2 (0.6) 4.2 (0.6) 4.3 (0.7)
HDL-c (mean, SD) (mmol/L) 1.3 (0.3) 1.3 (0.3) 1.4 (0.3)
LDL-c (mean, SD) (mmol/L) 2.4 (0.6) 2.3 (0.6) 2.4 (0.6)
Triglycerides
a
(geometric
mean, SD) (mmol/L)
1.0 (0.5) 1.1 (0.5) 1.5 (0.5)
Visits at 10 and 11 years
CITO score, standardized
(mean, SD)
0.0 (1.0) 0.2 (0.9) −0.3 (1.1)
Total brain volume (mean, SD)
(cm3)
1,200 (118) 1,225 (113) 1,168 (116)
Cortical volume (mean, SD)
(cm3)
574 (59) 588 (56) 556 (59)
Cerebrospinal ﬂuid volume
(mean, SD) (cm3)
0.9 (0.2) 0.9 (0.2) 0.9 (0.2)
Mean cortical thickness
(mean, SD) (mm)
2.67 (0.08) 2.68 (0.08) 2.67 (0.08)
Global FA, standardized
(mean, SD)
0.00 (1.00) 0.11 (0.97) −0.15 (1.02)
Global MD, standardized
(mean, SD)
0.00 (1.00) −0.03 (0.98) 0.04 (1.03)
Anxious/depressed scale
(mean, SD)
2.2 (2.7) 2.2 (2.7) 2.2 (2.6)
Withdrawn/depressed scale
(mean, SD)
1.1 (1.6) 1.1 (1.5) 1.1 (1.8)
Internalizing problems scale
(mean, SD)
4.7 (5.0) 4.5 (4.8) 5.1 (5.4)APOE, apolipoprotein epsilon.
IQ, intelligence quotient.
HDL-c, high density lipoprotein cholesterol.
LDL-c, low density lipoprotein cholesterol.
FA, fractional anisotropy.
MD, mean diffusivity.
aTriglyceride serum values were log-transformed.February 2020 | Volume 11 | Article 33
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responses to neuroinﬂammatory processes (66).
Interpreting the role ofAPOEinchildhoodbraindevelopment is
further complicated by the inconsistency of ﬁndings. Shaw and
colleagues found in children and adolescents that APOE e4 carriers
had thinner entorhinal cortices than non-carriers (25). Chang and
colleaguesalso studiedchildrenandadolescents, but they found that
e4 carriers had larger hippocampi than non-carriers (30).
Additionally, they report that e4 carriers compared to non-
carriers had larger volumes for the cuneus, the temporal pole, the
lateral occipital pole, and the medial orbitofrontal cortex. The two
studies that report thatAPOEaffects brain structure in infants show
that e4 carriers have smaller hippocampi thannon-carriers (28, 29).
Furthermore, they report that APOE affects regions that are very
different from those reported by Chang and colleagues (30). More
recently, Axelrud and colleagues reported that theADPGRS relates
to hippocampal volume in Brazilian children aged 6 to 14 years old
(53). However, the source GWAS on which the PGRS in the latter
study was based was performed in a population of European
ancestry (37). As we have shown, using the AD PGRS in
populations of non-European ancestry leads to false positiveFrontiers in Psychiatry | www.frontiersin.org 6ﬁndings. Indeed, Axelrud and colleagues could not replicate their
ﬁndings in a separate Canadian population of 1,024 adolescents. In
summary, previousﬁndings have been inconsistent, which suggests
that AD genetic burden may only affect early-life brain structure
under speciﬁc circumstances or that the effect is unlikely to be
clinically relevant.
We did not ﬁnd evidence in our study to suggest that AD
genetic burden affects cognitive functioning during childhood.
Previous studies on this topic report mixed results, but several
larger studies also did not ﬁnd evidence for such a link. Taylor and
colleagues studied cognition in the Avon Longitudinal Study of
Parents and Children (ALSPAC) study (23). The only pattern
observed was that APOE e4 carriers performed better on cognitive
tests than those with a APOE e3/e3 genotype, although not
statistically signiﬁcant. In our study we found no evidence to
support this. More recently, Weissberger and colleagues meta-
analyzed data from 9,234 individuals aged 2 to 40 years old and
found no association of APOE e4 carriership with intelligence,
attention, executive function, language, memory, processing
speed, and visuospatial abilities (67). In our study we conﬁrmed
this ﬁnding at two timepoints in childhood (around 6 years of ageFIGURE 1 | Heatmap showing the regression coefﬁcients between apolipoprotein E (APOE) genotype and all phenotypes. The E3/3 genotype is used as a reference
for the other genotypes. All coefﬁcients are standardized. The reported p-values were corrected for multiple testing. IQ, intelligence quotient; CBCL, Child Behavior
Checklist; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CSF, cerebrospinal ﬂuid; FA, fractional anisotropy; MD, mean diffusivity; * = 0.05; ** = 0.01;
*** = 0.001.February 2020 | Volume 11 | Article 33
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APOE e2 genotypes and to broader AD genetic burden. Taken
together, the literature and this study suggest that AD genetic
burden does not affect cognition during early life.Frontiers in Psychiatry | www.frontiersin.org 7The role of the APOE gene in serum lipid proﬁles during early
life has been studied before. In 2011, a study by Taylor and
colleagues assessed the relation between APOE status and serum
lipid proﬁles in 2,875 children aged 8 to 11 years from the ALSPACFIGURE 2 | Heatmap showing the regression coefﬁcients between the Alzheimer’s disease (AD) polygenic risk score (PGRS) and all phenotypes. Each score is
based on a different threshold for inclusion of single-nucleotide polymorphisms (SNPs) into the score. All coefﬁcients are standardized. The reported p-values were
corrected for multiple testing. IQ, intelligence quotient; CBCL, Child Behavior Checklist; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CSF,
cerebrospinal ﬂuid; FA, fractional anisotropy; MD, mean diffusivity; ** = 0.01; ** = 0.001.FIGURE 3 | Heatmap showing the regression coefﬁcients between the Parkinson’s disease (PD) polygenic risk score (PGRS) and all phenotypes. Each score is
based on a different threshold for inclusion of single-nucleotide polymorphisms (SNPs) into the score. All coefﬁcients are standardized. The reported p-values were
corrected for multiple testing. None of the associations were statistically signiﬁcant after correction. IQ, intelligence quotient; CBCL, Child Behavior Checklist; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; CSF, cerebrospinal ﬂuid; FA, fractional anisotropy; MD, mean diffusivity.February 2020 | Volume 11 | Article 33
Lamballais et al. Early-Life Relevance of Genetic Risk for Neurodegenerationcohort, a prospective birth cohort study (23). They showed that
carriership of APOE e2 was associated with reduced cholesterol and
increased triglyceride levels compared to APOE e3/e3, whereas
APOE e4 carriers had both elevated cholesterol and triglycerideFrontiers in Psychiatry | www.frontiersin.org 8levels. In 1997, Kallio and colleagues showed that cord blood from
42 APOE e4 carriers contained higher concentrations of cholesterol
than 13 carriers of APOE e2 (22). In addition, LDL levels rose
steeper during the ﬁrst year of life in the APOE e4 carriers than inFIGURE 4 | Heatmap showing the regression coefﬁcients between the frontotemporal dementia (FTD) polygenic risk score (PGRS) and all phenotypes. Each score
is based on a different threshold for inclusion of single-nucleotide polymorphisms (SNPs) into the score. All coefﬁcients are standardized. The reported p-values were
corrected for multiple testing. None of the associations were statistically signiﬁcant after correction. IQ, intelligence quotient; CBCL, Child Behavior Checklist; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; CSF, cerebrospinal ﬂuid; FA, fractional anisotropy; MD, mean diffusivity.FIGURE 5 | Scatterplots of log-transformed p-values when comparing different analyses. The results are shown for polygenic risk score (PGRS) thresholds
0.000001 (top row) and 1.000000 (bottom row). Comparisons are shown for European versus non-European (A, D), correcting for genomic components or not
(B, E), and European versus non-European when not correcting for genomic components (C, F). GC, genomic component.February 2020 | Volume 11 | Article 33
Lamballais et al. Early-Life Relevance of Genetic Risk for Neurodegenerationthe APOE e2 carriers. In our study we had similar ﬁndings for e2/e3
and e3/e4 but not for e2/e2 and e4/e4 genotypes, likely because
those genotypes were uncommon within the current study
population. Our ﬁndings further consolidate the causal role of
APOE genotype in serum lipid levels even during early life.
We found no evidence that PD and FTD genetic burden
inﬂuences early-life processes. However, the etiology and
pathogenesis of PD and FTD are poorly understood, and less is
known on the preclinical disease stage compared to AD. It is
therefore not clear how genetic burden for PD or FTD would
inﬂuence early-life processes. As both syndromes can occur
through dominant autosomal inheritance, it should be possible to
investigate families of PD or FTD patients to identify such
processes. However, we were unable to identify any such study in
the literature. Another route would be to look at healthy carriers of
knowngenetic risk variants for eitherPDorFTD to identify affected
processes. For example, the G2019S mutation in the LRRK2 gene,
the gene most widely associated with Parkinson’s disease, has been
studied in healthy controls. Different studies found this gene to be
associated with lower executive functioning (68), changes in gait
(69), olfactory dysfunction (70). However, all these studies were
small and exploratory. To the best of our knowledge, no studies
focusing on FTD candidate genes in healthy controls are available.
Further work is needed to elucidate whether PD and FTD genetic
burden play a role in other domains during early-life, for example
brain function rather than brain structure.
The etiology of AD, PD, and FTD extend beyond lipid proﬁles,
the brain, behavior, and cognition, thus raising the question which
other processes could be relevant during childhood. For example,
cerebrospinal ﬂuid markers levels such as Tau and phosphorylated
Tau are affected by APOE e4 carriership in demented individuals
(71–74). Inaddition,APOEprotein levels in cerebrospinalﬂuid, but
not blood serum, depend on the APOE genotype (75). Another
avenue for further research are inﬂammatory markers such as C-
reactive protein, interleukin-6, and a1-antichymotrypsin, which
have shownpredictivevalue for theonsetof all-causedementia (76).
Further assessment of endophenotypes closely related to speciﬁc
gene functionmay providemore stable ﬁndings related to early life.
Our ﬁndings may have been limited by several aspects of the
study design. First, we relied on cross-sectional data. Brain growth
follows non-linear trajectories, reaching a peak at around the age
when the children in our study underwent neuroimaging (77). The
genetic burdens for neurodegenerative disease may affect the
trajectories of brain development, which would only be detectable
through longitudinal studies. Alternatively, the genetic burden for
late-life neurodegenerative disease may not express until later in
childhood or adolescence, and the study population may simply be
too young for the researchquestions athand. Second, the number of
individuals with e2/e2 or e4/e4 genotypes was relatively low, thus
wewere likely underpowered to establish any small effects for those
genotypes. Third, we administered a limited number of cognitive
tests around the age of 6, limiting our investigation to non-verbal
IQ. AD is generally characterized by a loss of memory function, for
which we did not have an adequate test in children.
Our study also had clear strengths. The size of our study
population ensured sufﬁcient power to detect relatively smallFrontiers in Psychiatry | www.frontiersin.org 9effects related to the common APOE genotypes and the AD, PD,
and FTD PGRS. Furthermore, we provide an unambiguous case
for proper control of population stratiﬁcation, which was only
possible due to the large proportion of participants of non-
European ancestry. Finally, the Generation R study is a
representative sample from the general population, which
vastly improves the generalizability to a community-dwelling
population of European descent.
In conclusion, we found no evidence to support the role of
genetic burden for late-life neurodegenerative disease in early-life
cognitive performance, internalizing behavior, and brain metrics.
APOE genotype was related to blood lipid proﬁles. Genetic
burden for AD, PD, and FTD did not relate to cognition or
brain structure. These ﬁndings suggest that the etiology of late-
life neurodegenerative disease becomes only relevant later in life.
DATA AVAILABILITY STATEMENT
The datasets for this article are not automatically publicly
available due to legal and informed consent restrictions.
Reasonable requests to access the datasets should be directed
to the Director of the Generation R Study, Vincent Jaddoe
(generationr@erasmusmc.nl), in accordance with the local,
national and European Union regulations.
AUTHOR CONTRIBUTIONS
SL, RM, TW, and HA designed the project. SL analyzed the data.
SL and HA interpreted the results and drafted the article. All
authors contributed to manuscript revision, and read and
approved the submitted version. All authors agree to be
accountable for all of the published work.
FUNDING
The work was supported by the European Research Council
(ERC) under the European Union’s Horizon 2020 research and
innovation program (project: ORACLE, grant agreement No:
678543, and project JPco-fuND, grant agreement No: 643417),
the ZonMw (grant numbers 912.11.021 and 916.19.151), and the
Sophia Foundation (grant S18-20). The general design of
Generation R Study is made possible by ﬁnancial support from
the Erasmus Medical Center, Rotterdam, the Erasmus University
Rotterdam, the Netherlands Organization for Health Research
and Development (ZonMw), the Netherlands Organisation for
Scientiﬁc Research (NWO), the Ministry of Health, Welfare and
Sport, and the Ministry of Youth and Families.
ACKNOWLEDGMENTS
The Generation R Study is conducted by the Erasmus Medical
Center in close collaboration with the School of Law and Faculty
of Social Sciences of the Erasmus University Rotterdam, the
Municipal Health Service Rotterdam area, Rotterdam, the
Rotterdam Homecare Foundation, Rotterdam, and theFebruary 2020 | Volume 11 | Article 33
Lamballais et al. Early-Life Relevance of Genetic Risk for NeurodegenerationStichting Trombosedienst & Artsenlaboratorium Rijnmond
(STAR-MDC), Rotterdam. We gratefully acknowledge the
contribution of children and parents, general practitioners,
hospitals, midwives, and pharmacies in Rotterdam.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fpsyt.2020.
00033/full#supplementary-materialFrontiers in Psychiatry | www.frontiersin.org 10SUPPLEMENTARY FIGURE 1 | Flow chart of the study population.
SUPPLEMENTARY FIGURE 2 | Scatterplots of log-transformed p-values when
comparing analyses in the European versus non-European samples when
correcting for genomic components.
SUPPLEMENTARY FIGURE 3 | Scatterplots of log-transformed p-values when
comparing analyses corrected for genomic components versus not.
SUPPLEMENTARY FIGURE 4 | Scatterplots of log-transformed p-values when
comparing analyses in the European versus non-European samples when not
correcting for genomic components.REFERENCES
1. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al.
Genome-wide meta-analysis identiﬁes new loci and functional pathways
inﬂuencing Alzheimer’s disease risk. Nat Genet (2019) 51:404–13. doi:
10.1038/s41588-018-0311-9
2. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al.
Genetic meta-analysis of diagnosed Alzheimer’s disease identiﬁes new risk
loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet
(2019) 51:414–30. doi: 10.1038/s41588-019-0358-2
3. NallsMA, PankratzN, Lill CM,DoCB,HernandezDG, SaadM, et al. Large-scale
meta-analysis of genome-wide association data identiﬁes six new risk loci for
Parkinson’s disease. Nat Genet (2014) 46:989–93. doi: 10.1038/ng.3043
4. Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, et al.
Frontotemporal dementia and its subtypes: a genome-wide association study.
Lancet Neurol (2014) 13:686–99. doi: 10.1016/S1474-4422(14)70065-1
5. Jack CRJr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS,
et al. Tracking pathophysiological processes in Alzheimer’s disease: an
updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013)
12:207–16. doi: 10.1016/S1474-4422(12)70291-0
6. Postuma RB, Berg D. Prodromal Parkinson’s Disease: The Decade Past, the
Decade to Come. Mov Disord (2019) 34:665–75. doi: 10.1002/mds.27670
7. Staffaroni AM, Cobigo Y, Goh SM, Kornak J, Bajorek L, Chiang K, et al.
Individualized atrophy scores predict dementia onset in familial
frontotemporal lobar degeneration. Alzheimers Dement (2020) 1:37–48. doi:
10.1016/j.jalz.2019.04.007
8. Barnes DE, Yaffe K, Byers AL, Mccormick M, Schaefer C, Whitmer RA.
Midlife vs late-life depressive symptoms and risk of dementia: differential
effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry
(2012) 69:493–8. doi: 10.1001/archgenpsychiatry.2011.1481
9. Cherbuin N, Kim S, Anstey KJ. Dementia risk estimates associated with
measures of depression: a systematic review and meta-analysis. BMJ Open
(2015) 5:e008853. doi: 10.1136/bmjopen-2015-008853
10. Almeida OP, Hankey GJ, Yeap BB, Golledge J, Flicker L. Depression as a
modiﬁable factor to decrease the risk of dementia. Transl Psychiatry (2017) 7:
e1117. doi: 10.1038/tp.2017.90
11. Elias MF, Beiser A, Wolf PA, Au R, White RF, D’agostino RB. The preclinical
phase of alzheimer disease: A 22-year prospective study of the Framingham
Cohort. Arch Neurol (2000) 57:808–13. doi: 10.1001/archneur.57.6.808
12. Albanese E, Launer LJ, Egger M, Prince MJ, Giannakopoulos P, Wolters FJ,
et al. Body mass index in midlife and dementia: Systematic review and meta-
regression analysis of 589,649 men and women followed in longitudinal studies.
Alzheimers Dement (Amst) (2017) 8:165–78. doi: 10.1016/j.dadm.2017.05.007
13. Li G, LarsonEB, Shofer JB, Crane PK,Gibbons LE,MccormickW, et al. Cognitive
Trajectory Changes Over 20 Years Before Dementia Diagnosis:
ALargeCohort Study. JAmGeriatr Soc (2017)65:2627–33.doi: 10.1111/jgs.15077
14. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J,
Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and
increased frequency of type 4 allele in late-onset familial Alzheimer disease.
Proc Natl Acad Sci U S A (1993) 90:1977–81. doi: 10.1073/pnas.90.5.1977
15. Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, et al.
Association of CR1, CLU and PICALMwith Alzheimer’s disease in a cohort of
clinically characterized and neuropathologically veriﬁed individuals. Hum
Mol Genet (2010) 19:3295–301. doi: 10.1093/hmg/ddq22116. Stocker H, Mollers T, Perna L, Brenner H. The genetic risk of Alzheimer’s
disease beyond APOE epsilon4: systematic review of Alzheimer’s genetic risk
scores. Transl Psychiatry (2018) 8:166. doi: 10.1038/s41398-018-0221-8
17. Lin SK, Kao JT, Tsai SM, Tsai LY, Lin MN, Lai CJ, et al. Association of
apolipoprotein E genotypes with serum lipid proﬁles in a healthy population
of Taiwan. Ann Clin Lab Sci (2004) 34:443–8.
18. Alvim RO, Freitas SR, Ferreira NE, Santos PC, Cunha RS, Mill JG, et al. APOE
polymorphism is associated with lipid proﬁle, but not with arterial stiffness in the
general population. Lipids Health Dis (2010) 9:128. doi: 10.1186/1476-511X-9-128
19. El-Lebedy D, Raslan HM, Mohammed AM. Apolipoprotein E gene
polymorphism and risk of type 2 diabetes and cardiovascular disease.
Cardiovasc Diabetol (2016) 15:12. doi: 10.1186/s12933-016-0329-1
20. Kritharides L, Nordestgaard BG, Tybjaerg-Hansen A, Kamstrup PR, Afzal S.
Effect of APOE epsilon Genotype on Lipoprotein(a) and the Associated Risk
of Myocardial Infarction and Aortic Valve Stenosis. J Clin Endocrinol Metab
(2017) 102:3390–9. doi: 10.1210/jc.2017-01049
21. Shatwan IM, Winther KH, Ellahi B, Elwood P, Ben-Shlomo Y, Givens I, et al.
Association of apolipoprotein E gene polymorphisms with blood lipids and
their interaction with dietary factors. Lipids Health Dis (2018) 17:98. doi:
10.1186/s12944-018-0744-2
22. Kallio MJ, Salmenpera L, Siimes MA, Perheentupa J, Gylling H, Miettinen TA.
Apoprotein E phenotype determines serum cholesterol in infants during both
high-cholesterol breast feeding and low-cholesterol formula feeding. J Lipid
Res (1997) 38:759–64.
23. Taylor AE, Guthrie PA, Smith GD, Golding J, Sattar N, Hingorani AD, et al.
IQ, educational attainment, memory and plasma lipids: associations with
apolipoprotein E genotype in 5995 children. Biol Psychiatry (2011) 70:152–8.
doi: 10.1016/j.biopsych.2010.10.033
24. O’donoghue MC, Murphy SE, Zamboni G, Nobre AC, Mackay CE. APOE
genotype and cognition in healthy individuals at risk of Alzheimer’s disease: A
review. Cortex (2018) 104:103–23. doi: 10.1016/j.cortex.2018.03.025
25. Shaw P, Lerch JP, Pruessner JC, Taylor KN, Rose AB, Greenstein D, et al.
Cortical morphology in children and adolescents with different
apolipoprotein E gene polymorphisms: an observational study. Lancet
Neurol (2007) 6:494–500. doi: 10.1016/S1474-4422(07)70106-0
26. Filippini N, Macintosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM,
et al. Distinct patterns of brain activity in young carriers of the APOE-e4 allele
Distinct patterns Brain act In young carriers APOE-epsilon allele4. Proc Natl
Acad Sci U S A (2009) 106:7209–14. doi: 10.1073/pnas.0811879106
27. O’dwyer L, Lamberton F, Matura S, Tanner C, Scheibe M, Miller J, et al.
Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI
study. PloS One (2012) 7:e48895. doi: 10.1371/journal.pone.0048895
28. Dean DC3rd, Jerskey BA, Chen K, Protas H, Thiyyagura P, Roontiva A, et al.
Brain differences in infants at differential genetic risk for late-onset Alzheimer
disease: a cross-sectional imaging study. JAMA Neurol (2014) 71:11–22. doi:
10.1001/jamaneurol.2013.4544
29. Knickmeyer RC, Wang J, Zhu H, Geng X, Woolson S, Hamer RM, et al.
Common variants in psychiatric risk genes predict brain structure at birth.
Cereb Cortex (2014) 24:1230–46. doi: 10.1093/cercor/bhs401
30. Chang L, Douet V, Bloss C, Lee K, Pritchett A, Jernigan TL, et al. Gray matter
maturation and cognition in children with different APOE epsilon genotypes.
Neurology (2016) 87:585–94. doi: 10.1212/WNL.0000000000002939
31. Khera AV, Chafﬁn M, Aragam KG, Haas ME, Roselli C, Choi SH, et al.
Genome-wide polygenic scores for common diseases identify individuals withFebruary 2020 | Volume 11 | Article 33
Lamballais et al. Early-Life Relevance of Genetic Risk for Neurodegenerationrisk equivalent to monogenic mutations. Nat Genet (2018) 50:1219–24. doi:
10.1038/s41588-018-0183-z
32. Kooijman MN, Kruithof CJ, Van Duijn CM, Duijts L, Franco OH, Van IMH,
et al. The Generation R Study: design and cohort update 2017. Eur J Epidemiol
(2016) 31:1243–64. doi: 10.1007/s10654-016-0224-9
33. Jaddoe VW, Bakker R, Van Duijn CM, Van Der Heijden AJ, Lindemans J,
Mackenbach JP, et al. The Generation R Study Biobank: a resource for
epidemiological studies in children and their parents. Eur J Epidemiol
(2007) 22:917–23. doi: 10.1007/s10654-007-9209-z
34. Medina-Gomez C, Felix JF, Estrada K, Peters MJ, Herrera L, Kruithof CJ, et al.
Challenges in conducting genome-wide association studies in highly admixed
multi-ethnic populations: the Generation R Study. Eur J Epidemiol (2015)
30:317–30. doi: 10.1007/s10654-015-9998-4
35. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al.
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet (2007) 81:559–75. doi: 10.1086/519795
36. Euesden J, Lewis CM, O’reilly PF. PRSice: Polygenic Risk Score software.
Bioinformatics (2015) 31:1466–8. doi: 10.1093/bioinformatics/btu848
37. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C,
et al. Meta-analysis of 74,046 individuals identiﬁes 11 new susceptibility loci
for Alzheimer’s disease. Nat Genet (2013) 45:1452–8. doi: 10.1038/ng.2802
38. Tellegen PJ, Winkel M, Wijnberg-Williams B, Laros JA. SON-R 2,5-7: Snijder-
Oomen niet-verbale intelligentietest. Amsterdam: Hogrefe Uitgevers (2005).
39. Langeslag SJ, Schmidt M, Ghassabian A, Jaddoe VW, Hofman A, Van Der
Lugt A, et al. Functional connectivity between parietal and frontal brain
regions and intelligence in young children: the Generation R study. Hum
Brain Mapp (2013) 34:3299–307. doi: 10.1002/hbm.22143
40. Achenbach TM, Rescorla LA. Manual for the ASEBA preschool forms and
proﬁles. Burlington, VT: University of Vermont, Research center for children,
youth (2000).
41. White T, Muetzel RL, El Marroun H, Blanken LME, Jansen P, Bolhuis K, et al.
Paediatric population neuroimaging and the Generation R Study: the second
wave. Eur J Epidemiol (2018) 33:99–125. doi: 10.1007/s10654-017-0319-y
42. Fischl B. FreeSurfer. Neuroimage (2012) 62:774–81. doi: 10.1016/
j.neuroimage.2012.01.021
43. Muetzel RL, Blanken LME, Van Der Ende J, El Marroun H, Shaw P, Sudre G,
et al. Tracking Brain Development and Dimensional Psychiatric Symptoms in
Children: A Longitudinal Population-Based Neuroimaging Study. Am J
Psychiatry (2018) 175:54–62. doi: 10.1176/appi.ajp.2017.16070813
44. Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. Fsl.
Neuroimage (2012) 62:782–90. doi: 10.1016/j.neuroimage.2011.09.015
45. Chang LC, Jones DK, Pierpaoli C. RESTORE: robust estimation of tensors by
outlier rejection.Magn Reson Med (2005) 53:1088–95. doi: 10.1002/mrm.20426
46. De Groot M, Vernooij MW, Klein S, Ikram MA, Vos FM, Smith SM, et al.
Improving alignment in Tract-based spatial statistics: evaluation and
optimization of image registration. Neuroimage (2013) 76:400–11. doi:
10.1016/j.neuroimage.2013.03.015
47. Muetzel RL, Mous SE, Van Der Ende J, Blanken LM, Van Der Lugt A, Jaddoe
VW, et al. White matter integrity and cognitive performance in school-age
children: A population-based neuroimaging study. Neuroimage (2015)
119:119–28. doi: 10.1016/j.neuroimage.2015.06.014
48. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the preparative
ultracentrifuge. Clin Chem (1972) 18:499–502.
49. Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid
metabolism, neurobiology, and Alzheimer’s diseases. Neurobiol Dis (2014)
72:3–12. doi: 10.1016/j.nbd.2014.08.025
50. Core Team R. R: A language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing (2016).
51. Hellwege JN, Keaton JM, Giri A, Gao X, Velez Edwards DR, Edwards TL.
Population Stratiﬁcation in Genetic Association Studies. Curr Protoc Hum
Genet (2017) 18;95:1.22.1–1.22.23. doi: 10.1002/cphg.48
52. Quiroz YT, Schultz AP, Chen K, Protas HD, Brickhouse M, Fleisher AS, et al.
Brain Imaging and Blood Biomarker Abnormalities in Children With
Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study. JAMA
Neurol (2015) 72:912–9. doi: 10.1001/jamaneurol.2015.1099
53. Axelrud LK, Santoro ML, Pine DS, Talarico F, Gadelha A, Manfro GG, et al.
Polygenic Risk Score for Alzheimer’s Disease: Implications for MemoryFrontiers in Psychiatry | www.frontiersin.org 11Performance and Hippocampal Volumes in Early Life. Am J Psychiatry
(2018) 175:555–63. doi: 10.1176/appi.ajp.2017.17050529
54. Alexopoulos P, Richter-Schmidinger T, Horn M, Maus S, Reichel M,
Sidiropoulos C, et al. Hippocampal volume differences between healthy
young apolipoprotein E epsilon2 and epsilon4 carriers. J Alzheimers Dis
(2011) 26:207–10. doi: 10.3233/JAD-2011-110356
55. Heise V, Filippini N, Ebmeier KP, Mackay CE. The APOE varepsilon4 allele
modulates brain white matter integrity in healthy adults. Mol Psychiatry
(2011) 16:908–16. doi: 10.1038/mp.2010.90
56. Alexander GE, Bergﬁeld KL, Chen K, Reiman EM, Hanson KD, Lin L, et al.
Gray matter network associated with risk for Alzheimer’s disease in young to
middle-aged adults. Neurobiol Aging (2012) 33:2723–32. doi: 10.1016/
j.neurobiolaging.2012.01.014
57. Dibattista AM, Stevens BW, Rebeck GW, Green AE. Two Alzheimer’s disease
risk genes increase entorhinal cortex volume in young adults. Front Hum
Neurosci (2014) 8:779. doi: 10.3389/fnhum.2014.00779
58. Konishi K, Bhat V, Banner H, Poirier J, Joober R, Bohbot VD. APOE2 Is
Associated with Spatial Navigational Strategies and Increased Gray Matter in
the Hippocampus. Front Hum Neurosci (2016) 10:349. doi: 10.3389/
fnhum.2016.00349
59. Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW,
et al. Polygenic risk of Alzheimer disease is associated with early- and late-life
processes. Neurology (2016) 87:481–8. doi: 10.1212/WNL.0000000000002922
60. Foley SF, Tansey KE, Caseras X, Lancaster T, Bracht T, Parker G, et al.
Multimodal Brain Imaging Reveals Structural Differences in Alzheimer’s
Disease Polygenic Risk Carriers: A Study in Healthy Young Adults. Biol
Psychiatry (2017) 81:154–61. doi: 10.1016/j.biopsych.2016.02.033
61. Nao J, Sun H, Wang Q, Ma S, Zhang S, Dong X, et al. Adverse Effects of the
Apolipoprotein E epsilon4 Allele on Episodic Memory, Task Switching and
Gray Matter Volume in Healthy Young Adults. Front Hum Neurosci (2017)
11:346. doi: 10.3389/fnhum.2017.00346
62. Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker
LD, et al. Effect of apolipoprotein E genotype and diet on apolipoprotein E
lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol
(2013) 70:972–80. doi: 10.1001/jamaneurol.2013.396
63. Heinsinger NM, Gachechiladze MA, Rebeck GW. Apolipoprotein E Genotype
Affects Size of ApoE Complexes in Cerebrospinal Fluid. J Neuropathol Exp
Neurol (2016) 75:918–24. doi: 10.1093/jnen/nlw067
64. Ignatius MJ, Gebicke-Harter PJ, Skene JH, Schilling JW, Weisgraber KH,
Mahley RW, et al. Expression of apolipoprotein E during nerve degeneration
and regeneration. Proc Natl Acad Sci U S A (1986) 83:1125–9. doi: 10.1073/
pnas.83.4.1125
65. Arendt T, Schindler C, Bruckner MK, Eschrich K, Bigl V, Zedlick D, et al.
Plastic neuronal remodeling is impaired in patients with Alzheimer’s disease
carrying apolipoprotein epsilon 4 allele. J Neurosci (1997) 17:516–29. doi:
10.1523/JNEUROSCI.17-02-00516.1997
66. Tzioras M, Davies C, Newman A, Jackson R, Spires-Jones T. Invited Review:
APOE at the interface of inﬂammation, neurodegeneration and pathological
protein spread in Alzheimer’s disease. Neuropathol Appl Neurobiol (2019)
45:327–46. doi: 10.1111/nan.12529
67. Weissberger GH, Nation DA, Nguyen CP, Bondi MW, Han SD. Meta-
analysis of cognitive ability differences by apolipoprotein e genotype in
young humans. Neurosci Biobehav Rev (2018) 94:49–58. doi: 10.1016/
j.neubiorev.2018.08.009
68. Thaler A, Mirelman A, Gurevich T, Simon E, Orr-Urtreger A, Marder K, et al.
Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.
Neurology (2012) 79:1027–32. doi: 10.1212/WNL.0b013e3182684646
69. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff
JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann
Neurol (2011) 69:193–7. doi: 10.1002/ana.22165
70. Saunders-Pullman R, Stanley K, Wang C, San Luciano M, Shanker V, Hunt A,
et al. Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology
(2011) 77:319–24. doi: 10.1212/WNL.0b013e318227041c
71. Tapiola T, Lehtovirta M, Ramberg J, Helisalmi S, Linnaranta K, Riekkinen
PSr., et al. CSF tau is related to apolipoprotein E genotype in early Alzheimer’s
disease. Neurology (1998) 50:169–74. doi: 10.1212/WNL.50.1.169
72. Koch G, Di Lorenzo F, Loizzo S, Motta C, Travaglione S, Baiula M, et al. CSF
tau is associated with impaired cortical plasticity, cognitive decline andFebruary 2020 | Volume 11 | Article 33
Lamballais et al. Early-Life Relevance of Genetic Risk for Neurodegenerationastrocyte survival only in APOE4-positive Alzheimer’s disease. Sci Rep (2017)
7:13728. doi: 10.1038/s41598-017-14204-3
73. Van Harten AC, Jongbloed W, Teunissen CE, Scheltens P, Veerhuis R, Van
Der Flier WM. CSF ApoE predicts clinical progression in nondemented
APOEepsilon4 carriers. Neurobiol Aging (2017) 57:186–94. doi: 10.1016/
j.neurobiolaging.2017.04.002
74. HohmanTJ, Dumitrescu L, Barnes LL, ThambisettyM, BeechamG,Kunkle B, et al.
Sex-Speciﬁc Association of Apolipoprotein E With Cerebrospinal Fluid Levels of
Tau. JAMA Neurol (2018) 75:989–98. doi: 10.1001/jamaneurol.2018.0821
75. Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, et al.
Cerebrospinal ﬂuid APOE levels: an endophenotype for genetic studies for
Alzheimer’s disease.HumMol Genet (2012) 21:4558–71. doi: 10.1093/hmg/dds296
76. DarweeshSKL,Wolters FJ, IkramMA,DeWolf F, BosD,HofmanA. Inﬂammatory
markers and the risk of dementia and Alzheimer’s disease: A meta-analysis.
Alzheimers Dement (2018) 14:1450–9. doi: 10.1016/j.jalz.2018.02.014Frontiers in Psychiatry | www.frontiersin.org 1277. Shaw P, Kabani NJ, Lerch JP, Eckstrand K, Lenroot R, Gogtay N, et al.
Neurodevelopmental trajectories of the human cerebral cortex. J Neurosci
(2008) 28:3586–94. doi: 10.1523/JNEUROSCI.5309-07.2008
Conﬂict of Interest: The authors declare that the research was conducted in the
absence of any commercial or ﬁnancial relationships that could be construed as a
potential conﬂict of interest.
Copyright © 2020 Lamballais, Muetzel, Ikram, Tiemeier, Vernooij, White and
Adams. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) and the copyright owner(s) are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.February 2020 | Volume 11 | Article 33
